科研动态PubMed 摘要

中药联合EGFR-TKIs治疗EGFR突变晚期NSCLC:疗效与安全性的荟萃分析。

PubMed 学科轮询 · 2026-10-12

完整摘要 · 中文译文

目的:对于晚期表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC),表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗是主要治疗手段,但耐药和不良反应会降低其疗效。中西医结合是肿瘤治疗的重点方向。本研究评估中医药(TCM)联合EGFR-TKI的临床获益,并总结中医证型及用药特点。 方法:我们检索了六个数据库中的相关临床研究。通过荟萃分析评估无进展生存期(PFS)、疾病控制率(DCR)和不良反应,并按EGFR突变类型进行亚组分析。构建中医证型网络以考察证型分布和核心处方规律。 结果:中医药联合EGFR-TKI显著改善PFS(HR = 0.70,95%CI 0.65-0.76,p < 0.00001,I² = 0%),外显子19缺失或L858R突变患者获益相当(p = 0.75)。联合治疗提高了DCR(RR = 1.19,95% CI 1.01-1.40,p = 0.04),异质性较大(I² = 89%),并减少了靶向药物相关不良反应。气阴两虚和肺脾两虚是主要中医证型,通过益气、养阴和健脾方案进行辨治。 结论:中医药联合EGFR-TKI可增强EGFR突变晚期NSCLC患者的肿瘤控制并提高治疗安全性,在不同突变类型中显示出 consistent 疗效。该方法结合了中医临床辨证和用药规律。 医学,为个体化治疗提供循证指导。本综述按照PRISMA 2020指南进行。 系统综述注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420261398486,注册号CRD420261398486。

完整摘要 · 英文原文

OBJECTIVE: For advanced EGFR-mutant non-small cell lung cancer (NSCLC), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) therapy is the primary treatment, but drug resistance and side effects reduce its effectiveness. Integrating Chinese and Western medicine is a key focus in cancer treatment. This study evaluates the clinical benefits of combining traditional Chinese medicine (TCM) with EGFR-TKI, summarizing TCM syndromes and medication traits. METHODS: We searched six databases for relevant clinical studies. A meta-analysis assessed progression-free survival (PFS), disease control rate (DCR), and adverse reactions, with subgroup analysis by EGFR mutation type. A TCM syndrome network was created to examine syndrome distribution and core prescription patterns. RESULTS: TCM combined with EGFR-TKIs significantly improved PFS (HR = 0.70, 95%CI 0.65-0.76, p < 0.00001, I² = 0%), benefiting patients with Exon 19 deletion or L858R mutation equally (p = 0.75). The combination therapy increased DCR (RR = 1.19, 95% CI 1.01-1.40, p = 0.04), with substantial heterogeneity (I² = 89%), and reduced targeted-agent-related adverse reactions. Qi-Yin and Lung-Spleen deficiency were the dominant TCM syndromes, managed via Qi-tonifying, Yin-nourishing and spleen-strengthening regimens. CONCLUSION: Integrating TCM with EGFR-TKI enhances tumor control and treatment safety in advanced NSCLC patients with EGFR mutations, showing consistent efficacy across various mutation types. This approach, which considers clinical syndrome differentiation and medication patterns in Chinese medicine, offers evidence-based guidance for personalized treatment. This review was performed following the PRISMA 2020 guidelines. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261398486, identifier CRD420261398486.

English
Chinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safety.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界